| Valley Vision Care, P.a. | |
|
10480 Garverdale Ct, Ste 806, Boise, ID 83704 | |
| (208) 322-1771 | |
| (208) 377-9703 |
| Full Name | Valley Vision Care, P.a. |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 10480 Garverdale Ct, Boise, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194920421 | NPI | - | NPPES |
| V3660 | Other | ID | BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Valley Vision Care, P.a. 10480 Garverdale Ct, Ste 806, Boise, ID 83704 Ph: (208) 322-1771 | Valley Vision Care, P.a. 10480 Garverdale Ct, Ste 806, Boise, ID 83704 Ph: (208) 322-1771 |
News Archive
Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD).
The drug known as ecstasy has been used by 12 million people in the United States alone and millions more worldwide. Past research has suggested that ecstasy users perform worse than nonusers on some tests of mental ability. But there are concerns that the methods used to conduct that research were flawed, and the experiments overstated the cognitive differences between ecstasy users and nonusers.
AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo
On the eve of World Alzheimer's Day, the Alzheimer Society of Canada has called on the Federal Government to immediately establish a Canadian Alzheimer's disease and dementia partnership to lead and facilitate the development and implementation of a national dementia strategy.
› Verified 6 days ago
Vision Quest Medical Center, Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5680 W Gage St, Boise, ID 83706 Phone: 208-377-3937 Fax: 208-377-9455 | |
Dr. Gregory N Bodily, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 610 Americana Blvd, Boise, ID 83702 Phone: 208-344-2020 Fax: 208-344-2371 | |
Brent Sexauer, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1175 W Boise Ave, Boise, ID 83706 Phone: 208-384-9194 | |
J. Randall Pitman & Associates, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 2051 S Cole Rd, Boise, ID 83709 Phone: 208-672-1200 Fax: 208-321-8728 | |
Dr. James W Vail, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3417 N Cole Rd, Boise, ID 83704 Phone: 208-377-1102 Fax: 208-377-5853 | |
Dr. Lavar W Kofoed, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 291 N Milwaukee St, Boise, ID 83704 Phone: 208-378-7020 Fax: 208-378-9460 | |
Dr. Paul Christian Neville, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 305 E Jefferson St, Boise, ID 83712 Phone: 208-381-6910 |